Format

Send to:

Choose Destination
See comment in PubMed Commons below
Br J Dermatol. 2013 Jul;169(1):125-9. doi: 10.1111/bjd.12417.

Propranolol-resistant infantile haemangiomas.

Author information

  • 1Department of Dermatology, Centre Hospitalier Universitaire Hôtel-Dieu, 1 place Alexis-Ricordeau, 44093 Nantes Cedex 1, France.

Abstract

BACKGROUND:

Propranolol is now widely used to treat severe infantile haemangiomas (IHs). Very few cases of propranolol-resistant IH (PRIH) are mentioned in the literature.

OBJECTIVES:

To describe the characteristics of PRIHs.

METHODS:

A national, multicentre, retrospective, observational study was conducted from February 2011 to December 2011. All patients with PRIH evaluated by the members of the Groupe de Recherche Clinique en Dermatologie Pédiatrique from 1 January 2007 to 1 December 2011 were eligible.

RESULTS:

Among 1130 patients treated with propranolol for infantile haemangioma, 10 (0.9%) had PRIHs. Haemangioma propranolol resistance was observed at all ages during early childhood and at any proliferation stage.

CONCLUSIONS:

PRIH is a rare phenomenon that raises questions and merits further investigation.

© 2013 British Association of Dermatologists.

PMID:
23659587
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Blackwell Publishing
    Loading ...
    Write to the Help Desk